Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880967 | 0.95 | CA1 (0.49) | KCNA3CA1CA2CA9CA12 | |
| SCHEMBL411103 | 0.90 | CA2 (0.54) | KCNA3CA1CA2CA9CA12 | |
| SCHEMBL8355995 | 0.83 | CA2 (0.48) | CA1CA2CA9CA12CA7 | |
| SCHEMBL10553004 | 0.80 | ADRB2 (0.46) | CA1CA2CA9CA12CA7 | |
| SCHEMBL10550048 | 0.80 | ADRB2 (0.46) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1128972 | 0.80 | CA2 (0.51) | CA1CA2CA9CA12CA7 | |
| SCHEMBL21092385 | 0.80 | ADRB2 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1809375 | 0.78 | CA2 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL6671590 | 0.78 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL8349565 | 0.77 | CA2 (0.54) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212920-A1 | N-Substituted Benzene Sulfonamides | NEITZEL MARTIN | 2011-09-01 | — | — | US | disclosed |
| US-7939657-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-7208488-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | ELAN PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | BACE1, PSEN1, BACE2 | KCNA3 2737/4885CA1 839/4885CA2 3100/4885 |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | KCNA3 1759/4885CA1 591/4885CA2 3239/4885 |
| US-20110212920-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | KCNA3 1759/4885CA1 591/4885CA2 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.